Acubiosys, incubated at Hyderabad’s Centre for DNA Fingerprinting and Diagnostics, has used AI-driven molecular screening and nanotechnology to turn plant compounds into two patented, GMP-certified treatments for chronic skin disorders and diabetic foot ulcers
Somewhere between a supercomputer’s screen and a diabetic patient’s wound dressing lies a rather elegant piece of modern science: teaching artificial intelligence to comb through the plant kingdom for molecules good enough to become medicine. That’s exactly what Hyderabad-based start-up Acubiosys has managed to do — and the result is two new, patented treatments now available for chronic skin conditions and diabetic wound care.
The Problem With Finding New Drugs the Old Way
Traditional drug discovery is notoriously slow and expensive. Researchers typically test compounds one by one — sometimes over years — before finding a molecule that’s both effective and safe enough to become a viable treatment. When your target is something as biologically complex as psoriasis (a chronic autoimmune skin disorder) or chronic diabetic inflammation (which can lead to painful, slow-healing foot ulcers), the number of potential molecular candidates worth testing can run into the thousands.
This is exactly the kind of haystack-and-needle problem AI is increasingly being deployed to solve.
Teaching AI to Read Nature’s Pharmacy
Acubiosys, incubated at the Centre for DNA Fingerprinting and Diagnostics (CDFD), deployed advanced AI algorithms to scan massive botanical databases, paired with 3D molecular modelling to virtually screen thousands of plant-derived compounds at once. Instead of testing molecules physically in a lab one at a time, the AI could predict — computationally, in advance — which specific molecules and combinations were most likely to effectively target complex conditions like psoriasis, dermatitis, and chronic diabetic inflammation.
Think of it as swapping blind trial-and-error for a highly educated shortlist — the AI doesn’t invent new chemistry, but it dramatically narrows down which of nature’s existing molecules are worth pursuing, saving enormous amounts of time and lab resources in the early screening phase.
From Algorithm to Actual Medicine
The computational work didn’t stay theoretical. Acubiosys has successfully commercialised two patented, nanotechnology-enabled topical formulations built on this AI-driven discovery process:
- BOCUGL — for the management of psoriasis, dermatitis, and melasma
- AZBECO — an advanced wound-care formulation specifically designed for diabetic foot ulcers
Both products have reportedly been manufactured in India under strict Good Manufacturing Practices (GMP) and AYUSH regulatory compliance, and the underlying technology platforms have been filed for patents across multiple jurisdictions, including India, China, and the United States.
Why Nanotechnology Is the Real Delivery Trick
Identifying the right plant compound is only half the battle — getting it to actually work once applied to skin is the other. This is where nanotechnology plays a critical, almost invisible, role in these formulations.
Skin is naturally an excellent barrier — that’s precisely its job. So Acubiosys’s approach encapsulates the AI-optimised plant active ingredients into microscopic nanoparticles, small enough to bypass the skin’s tough outer layer and deliver therapeutic compounds directly to deep, inflamed tissue — the exact site where conditions like psoriasis or diabetic ulcers cause damage. Without this kind of targeted delivery mechanism, even a perfectly identified “wonder molecule” might simply sit on the skin’s surface, doing little good.
Built on Rigorous Preclinical Groundwork
Commenting on the development, Dr Srinivas Maddi, Founder and CEO of Acubiosys Private Limited, credited the CDFD Technology Incubator’s research infrastructure as instrumental in conducting the critical preclinical and animal studies needed to validate the technology before it could move toward commercialisation.
A Bigger Signal for India’s Biotech Sector
Beyond the two products themselves, this development is a useful case study in where drug discovery is headed globally: the convergence of AI-driven computational screening, nanotechnology-based delivery systems, and traditional plant-based pharmacology — sometimes dubbed “AI-powered phytomedicine.”
For India’s biotech ecosystem, still building its reputation in original drug discovery rather than just generic manufacturing, a homegrown start-up taking AI-screened molecules all the way from a CDFD lab to GMP-certified, patented products is a small but meaningful marker of progress — one that suggests the country’s incubator-and-start-up pipeline is beginning to produce not just promising research papers, but real, shelf-ready treatments.
